Aclaris Therapeutics (NASDAQ:ACRS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Aclaris Therapeutics beat estimated earnings by 22.5%, reporting an EPS of $-0.31 versus an estimate of $-0.4.
Revenue was down $324.00 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01 which was followed by a 8.64% increase in the share price the next day.
Here's a look at Aclaris Therapeutics's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.36 | -0.28 | -0.29 | -0.29 |
| EPS Actual | -0.37 | -0.35 | -0.34 | -0.57 |
| Revenue Estimate | 1.79M | 1.77M | 1.69M | 1.69M |
| Revenue Actual | 1.50M | 1.66M | 1.82M | 1.78M |
To track all earnings releases for Aclaris Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
